Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
作者： Francesca Battaglin , Vincenzo Dadduzio , Francesca Bergamo , Chiara Manai , Marta Schirripa
DOI: 10.1080/14712598.2017.1356815
关键词: Oncology 、 Colorectal cancer 、 Monoclonal antibody 、 Panitumumab 、 Primary tumor 、 Pharmacodynamics 、 Chemotherapy 、 Epidermal growth factor receptor 、 Gene mutation 、 Internal medicine 、 Medicine
摘要: ABSTRACTIntroduction: Targeted agents alone or in combination with chemotherapy are current standard of treatment for metastatic colorectal cancer (mCRC). Panitumumab is a fully human monoclonal antibody which inhibits the epidermal growth factor receptor (EGFR). It currently approved first- and second-line as monotherapy chemorefractory patients. RAS gene mutations confer resistance to anti-EGFR agents; thus, panitumumab restricted wild-type (WT) tumors.Areas covered: This review explores available data on and presents new perspectives predictive markers efficacy including primary tumor sidedness BRAF mutations. Other details covered include panitumumab’s mechanism action, pharmacokinetics, pharmacodynamics safety aspects therapy well mechanisms secondary future prospects different settings.Expert opinion: has significantly added ...
elsevier.com
sci-hub.se 参考文章(79)
Chiara Cremolini, Marta Schirripa, Carlotta Antoniotti, Roberto Moretto, Lisa Salvatore, Gianluca Masi, Alfredo Falcone, Fotios Loupakis, First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nature Reviews Clinical Oncology. ,vol. 12, pp. 607- 619 ,(2015) , 10.1038/NRCLINONC.2015.129
Andrew Rowland, Mafalda M Dias, Michael D Wiese, Ganessan Kichenadasse, Ross A McKinnon, Christos S Karapetis, Michael J Sorich, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. British Journal of Cancer. ,vol. 112, pp. 1888- 1894 ,(2015) , 10.1038/BJC.2015.325
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, Giorgio Corti, Andrea Cassingena, Giovanni Crisafulli, Agostino Ponzetti, Chiara Cremolini, Alessio Amatu, Calogero Lauricella, Simona Lamba, Sebastijan Hobor, Antonio Avallone, Emanuele Valtorta, Giuseppe Rospo, Enzo Medico, Valentina Motta, Carlotta Antoniotti, Fabiana Tatangelo, Beatriz Bellosillo, Silvio Veronese, Alfredo Budillon, Clara Montagut, Patrizia Racca, Silvia Marsoni, Alfredo Falcone, Ryan B Corcoran, Federica Di Nicolantonio, Fotios Loupakis, Salvatore Siena, Andrea Sartore-Bianchi, Alberto Bardelli, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients Nature Medicine. ,vol. 21, pp. 795- 801 ,(2015) , 10.1038/NM.3870
Mareike Voigt, Friederike Braig, Markus Göthel, Alexander Schulte, Katrin Lamszus, Carsten Bokemeyer, Mascha Binder, Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab Neoplasia. ,vol. 14, pp. 1023- 1031 ,(2012) , 10.1593/NEO.121242
Peter J. O’Dwyer, Judith Manola, Frank H. Valone, Louise M. Ryan, John D. Hines, Scott Wadler, Daniel G. Haller, Susan G. Arbuck, Louis M. Weiner, Robert J. Mayer, Al B. Benson, Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study Journal of Clinical Oncology. ,vol. 19, pp. 2413- 2421 ,(2001) , 10.1200/JCO.2001.19.9.2413
Edith P. Mitchell, Bilal Piperdi, Mario E. Lacouture, Heather Shearer, Nicholas Iannotti, Madhavan V. Pillai, Feng Xu, Mohamed Yassine, The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clinical Colorectal Cancer. ,vol. 10, pp. 333- 339 ,(2011) , 10.1016/J.CLCC.2011.06.004
Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609
Claudia Esposito, Anna Maria Rachiglio, Maria Libera La Porta, Alessandra Sacco, Cristin Roma, Alessia Iannaccone, Fabiana Tatangelo, Laura Forgione, Raffaella Pasquale, Americo Barbaro, Gerardo Botti, Fortunato Ciardiello, Nicola Normanno, The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biology & Therapy. ,vol. 14, pp. 1143- 1146 ,(2013) , 10.4161/CBT.26340
Filippo Pietrantonio, Fausto Petrelli, Andrea Coinu, Maria Di Bartolomeo, Karen Borgonovo, Claudia Maggi, Mary Cabiddu, Roberto Iacovelli, Ilaria Bossi, Veronica Lonati, Mara Ghilardi, Filippo de Braud, Sandro Barni, Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis European Journal of Cancer. ,vol. 51, pp. 587- 594 ,(2015) , 10.1016/J.EJCA.2015.01.054
Andrea Bertotti, Giorgia Migliardi, Francesco Galimi, Francesco Sassi, Davide Torti, Claudio Isella, Davide Corà, Federica Di Nicolantonio, Michela Buscarino, Consalvo Petti, Dario Ribero, Nadia Russolillo, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Luca Molinaro, Emanuele Valtorta, Andrea Sartore-Bianchi, Mauro Risio, Lorenzo Capussotti, Marcello Gambacorta, Salvatore Siena, Enzo Medico, Anna Sapino, Silvia Marsoni, Paolo M Comoglio, Alberto Bardelli, Livio Trusolino, None, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery. ,vol. 1, pp. 508- 523 ,(2011) , 10.1158/2159-8290.CD-11-0109